Patient and Caregiver Survey on Benefits and Risks of Potential Treatments for Nonalcoholic Steatohepatitis (NASH)

All people who currently have or previously had nonalcoholic steatohepatitis (NASH), or their caregiver, are invited by Global Liver Institute and the Liver Action Network to participate in an important survey. This survey acts as the critical backdrop to the Externally Led Patient Focused Drug Development (PFDD) Meeting Global Liver Institute is currently planning for November 4th.

This survey is designed to collect anonymous information about your priorities and preferences for addressing NASH including issues centered around diagnosis, clinical trial access, and available treatment options. Data from this survey will be used by Global Liver Institute, a 501(c)3 patient advocacy and support organization, for research in our mission to help develop potential treatments for NASH. This information will also be shared with the U.S. Food and Drug Administration, the Liver Action Network, and a variety of other stakeholders within the medical community to help them understand your thoughts and feelings about potential treatments for NASH.

Participation in this survey is optional and should take about 20 minutes. Responses will be kept confidential. Any data collected in this survey will only be shared in an anonymized fashion and the survey organizers will not contact anyone about their responses.

If you have any questions, please let us know by reaching out to Andrew Scott, ascott@globalliver.org.